Screener
Aquestive Therapeutics, Inc. AQST Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Numerator: | ||||
| Net loss | $(22,864) | $(13,548) | $(30,921) | $(36,478) |
| Denominator: | ||||
| Weighted-average number of common shares – basic and diluted | 124,994,165 | 99,326,701 | 123,808,666 | 97,422,458 |
| Loss per common share – basic and diluted | $(0.18) | $(0.14) | $(0.25) | $(0.37) |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s shares (diluted)?
- Aquestive Therapeutics, Inc. (AQST) reported shares (diluted) of 125M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Aquestive Therapeutics, Inc.'s shares (diluted) increased by 25.8% year-over-year, from 99.3M to 125M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s shares (diluted) has grown at a 28.8% compound annual growth rate (CAGR), from 149.9M to 412.3M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Aquestive Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude